Premium
R‐CHOP/R‐HDAC AND RITUXIMAB MAINTENANCE RESULTS IN HIGH COMPLETE REMISSION RATE, MINIMAL RESIDUAL DISEASE NEGATIVITY, AND EXCELLENT SURVIVAL IN ELDERLY MCL PATIENTS
Author(s) -
Klener P.,
Fronkova E.,
Belada D.,
Forsterova K.,
Pytlik R.,
Kalinova M.,
Simkovic M.,
Salek D.,
Mocikova H.,
Prochazka V.,
Blahovcová P.,
Janikova A.,
Markova J.,
Obr A.,
Berkova A.,
Vaskova M.,
Mejstrikova E.,
Campr V.,
Kubinyi J.,
Jaksa R.,
Kodet R.,
Michalova K.,
Trka J.,
Trneny M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_68
Subject(s) - medicine , minimal residual disease , rituximab , mantle cell lymphoma , cytarabine , chop , gastroenterology , lymphoma , oncology , transplantation , international prognostic index , autologous stem cell transplantation , maintenance therapy , surgery , bone marrow , leukemia , chemotherapy